方达(01521.HK)续涨12%成交倍增 获里昂升级至「买入」
方达控股(01521.HK)获里昂将评级由「跑赢大市」上调至「买入」看5.97元。该股今早平开曾回落至4.55元拒绝再下,掉头向上,午後高见5.2元,创逾三个月高,现造5.13元,续涨12%,成交倍增至3,313万股,涉资1.6亿元。
方达是一间发展迅速、协助制药公司实现药物开发目标的合同研究机构,公司於中美两大市场均拥有业务。股份去年5月尾以每股3.2元上市後,曾於6月反覆见2.89元获承接,之後回升,去年10月尾一度升至5.83元新高遇阻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.